基于CIBERSORTx的免疫细胞评分系统可独立预测MDS患者预后
该研究采用CIBERSORTx估算316例MDS患者骨髓中22种免疫细胞亚型的相对比例,发现M0巨噬细胞比例低、M2巨噬细胞和嗜酸性粒细胞比例高与生存较差显著相关,据此构建免疫细胞评分系统(ICSS)。ICSS可将患者分为3个风险组,白血病无进展生存和总生存差异显著,并在独立队列中验证,多因素分析显示ICSS可独立预测预后。
要点
- 骨髓M0巨噬细胞比例低、M2巨噬细胞和嗜酸性粒细胞比例高与MDS患者生存较差显著相关。
- 基于上述3种免疫细胞构建的ICSS可将MDS患者分为3个风险组,白血病无进展生存和总生存差异显著。
- ICSS在多因素分析中可独立预测预后,不受年龄、IPSS-R和突变状态影响。
核心结论
- 基于骨髓3种免疫细胞比例的ICSS可独立预测MDS患者预后,并在独立队列中验证。
研究设计与样本
- 采用CIBERSORTx估算316例MDS患者骨髓中22种免疫细胞亚型的相对比例,并与临床结局关联。
- 构建基于3种免疫细胞比例的ICSS,并在另一独立队列中验证其预后意义。
主要发现
- M0巨噬细胞比例较低、M2巨噬细胞和嗜酸性粒细胞比例较高与生存较差显著相关。
- ICSS高风险患者骨髓原始细胞计数更高、不良细胞遗传学频率更高,且NPM1、TP53和WT1突变更多。
- ICSS可将总队列及按IPSS-R划分的低危和高危亚组患者分为3个风险组,白血病无进展生存和总生存差异显著。
- 多因素分析显示ICSS可独立预测预后,不受年龄、IPSS-R和突变状态影响。
- 生物信息学分析显示高风险ICSS与核因子κB信号、氧化应激和白血病干细胞特征通路显著相关。
关键数值与推荐
- ICSS基于骨髓中M0巨噬细胞、M2巨噬细胞和嗜酸性粒细胞的相对比例构建。
- ICSS将患者分为3个风险组,组间白血病无进展生存和总生存差异显著。
临床怎么用
- ICSS或可作为MDS患者预后分层工具,辅助独立于IPSS-R和突变状态的预后评估。
局限性
- 需进一步研究干细胞与免疫细胞间相互作用的机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aside from cell intrinsic factors such as genetic alterations, immune dysregulation in the bone marrow (BM) microenvironment plays a role in the development and progression of myelodysplastic syndromes (MDS). However, the prognostic implications of various immune cells in patients with MDS remain unclear. We adopted CIBERSORTx to estimate the relative fractions of 22 subtypes of immune cells in the BM of 316 patients with MDS and correlated the results with clinical outcomes. A lower fraction of unpolarized M0 macrophages and higher fractions of M2 macrophages and eosinophils were significantly associated with inferior survival. An immune cell scoring system (ICSS) was constructed based on the proportion of these 3 immune cells in the BM. The ICSS high-risk patients had higher BM blast counts, higher frequencies of poor-risk cytogenetics, and more NPM1, TP53, and WT1 mutations than intermediate- and low-risk patients. The ICSS could stratify patients with MDS into 3 risk groups with distinct leukemia-free survival and overall survival among the total cohort and in the subgroups of patients with lower and higher disease risk based on the revised International Prognostic Scoring System (IPSS-R). The prognostic significance of ICSS was also validated in another independent cohort. Multivariable analysis revealed that ICSS independently predicted prognosis, regardless of age, IPSS-R, and mutation status. Bioinformatic analysis demonstrated a significant correlation between high-risk ICSS and nuclear factor κB signaling, oxidative stress, and leukemic stem cell signature pathways. Further studies investigating the mechanistic insight into the crosstalk between stem cells and immune cells are warranted.
引用
- Wang YH, Hou HA, Lin CC, et al. A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes. Blood Adv. 2021. PMID: 34614508. doi:10.1182/bloodadvances.2021005141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。